ATF4 and acute myeloid leukemia: As more and more evidences show that the identification of new AML biomarkers contributes to a better understanding of the molecular basis of the disease, we hope that ATF4, as a biomarker and the potential therapeutic target, will be significantly useful in diagnosis and prognosis for elderly AML patients, as well as the possibility of indicating new therapeutic strategies [13, 30].